Survival benefit of nephroureterectomy in systemic therapy exposed metastatic upper tract urinary urothelial carcinoma patients

Simone Morra,Reha-Baris Incesu,Lukas Scheipner,Andrea Baudo,Letizia Maria Ippolita Jannello,Carolin Siech,Mario de Angelis,Zhe Tian,Massimiliano Creta,Gianluigi Califano,Claudia Collà Ruvolo,Fred Saad,Shahrokh F. Shariat,Felix K. H. Chun,Ottavio de Cobelli,Gennaro Musi,Alberto Briganti,Derya Tilki,Sascha Ahyai,Luca Carmignani,Nicola Longo,Pierre I. Karakiewicz
DOI: https://doi.org/10.1007/s00345-024-05057-3
2024-05-23
World Journal of Urology
Abstract:It is unknown whether the stage of the primary may influence the survival (OS) of metastatic upper tract urothelial carcinoma (mUTUC) patients treated with nephroureterectomy (NU) and systemic therapy (ST). We tested this hypothesis within a large-scale North American cohort.
urology & nephrology
What problem does this paper attempt to address?